Combination therapy for HR-positive, HER2-negative cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone receptor-positive (HR-positive) and HER2-negative cancer that is a solid tumor.
- You are able to understand the trial and agree to participate.
- Your bone marrow and major organs (like liver and kidneys) are working well enough.
- You have not used the drug fulvestrant before.
- You do not have active brain tumors, uncontrolled heart disease, or serious ongoing health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.